BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25778881)

  • 21. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
    Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
    Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
    Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.
    Tovar N; Fernández de Larrea C; Elena M; Cibeira MT; Aróstegui JI; Rosiñol L; Filella X; Yagüe J; Bladé J
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1076-9. PubMed ID: 22430087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation and comparison of prognostic value of serum free light chain ratio/difference in patients with newly diagnosed multiple myeloma].
    Li L; Jiang H; Fu WJ; Du J; He HY; Lu J; An R; He J; Zhang H; Zhao YY; Wu H; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):321-326. PubMed ID: 31104445
    [No Abstract]   [Full Text] [Related]  

  • 26. Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.
    Michallet M; Chapuis-Cellier C; Dejoie T; Lombard C; Caillon H; Sobh M; Moreau P; Attal M; Avet-Loiseau H
    Leukemia; 2018 Feb; 32(2):376-382. PubMed ID: 28663581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative analysis of three serum-free light-chain detection systems in the diagnosis of multiple myeloma.
    Zhu G; Fu X; Ren Y; Wang Y; Wang S; An G
    Int J Lab Hematol; 2022 Jun; 44(3):576-581. PubMed ID: 35060324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Within-subject biological variation of pairs of heavy/light immunoglobulin IgM chains (HLC IgM κ and λ) is low and requires monitoring: A comparison with HLC IgA, HLC IgG, and free light immunoglobulin chains (FLC) in healthy subjects.
    Jabor A; Kubíček Z; Komrsková J; Sečník P; Vacková T; Vymětalík J; Franeková J
    Clin Chim Acta; 2018 Nov; 486():311-312. PubMed ID: 30125534
    [No Abstract]   [Full Text] [Related]  

  • 29. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
    Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
    Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma.
    Guo Z; Li H; Geng Y; Cui J; Tang N; Li D
    Am J Med Sci; 2018 Apr; 355(4):350-356. PubMed ID: 29661348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Free light chains and heavy/light chains in monitoring POEMS patients.
    Altinier S; Proko K; Zaninotto M; Ciubotaru D; Seguso M; Varagnolo M; Lessi F; Briani C; Adami F; Plebani M
    Clin Chem Lab Med; 2016 Jun; 54(6):1065-71. PubMed ID: 27071150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
    Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
    Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Two Serum Free Light Chain Detection Systems in the Diagnosis of Multiple Myeloma].
    Zhu GQ; Fu X; Ren YS; Wang YS; Wang SL; Wang LC; Lin J; An G
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1209-1215. PubMed ID: 34362504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
    Harutyunyan NM; Vardanyan S; Ghermezi M; Gottlieb J; Berenson A; Andreu-Vieyra C; Berenson JR
    Br J Haematol; 2016 Jul; 174(1):81-7. PubMed ID: 27017948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
    Chen HF; Hou J; Yuan ZG; Wang DX; Fu WJ; Chen YB
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):113-6. PubMed ID: 18681313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite™) assays for diagnosing and monitoring monoclonal gammopathies.
    Kraj M
    Adv Clin Exp Med; 2014; 23(1):127-33. PubMed ID: 24596015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
    Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
    Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.
    Isola I; Moreno DF; Moga E; Mena MP; Tovar N; Rodríguez-Lobato LG; Oliver-Caldés A; Salgado MC; Brasó-Maristany F; Yagüe J; Cibeira MT; Prat A; Rosiñol L; Bladé J; Fernández de Larrea C
    Ann Hematol; 2021 Dec; 100(12):2997-3005. PubMed ID: 34463804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.